FLAGSHIP HARBOR ADVISORS, LLC - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 439 filers reported holding CRISPR THERAPEUTICS AG in Q3 2022. The put-call ratio across all filers is 0.94 and the average weighting 0.2%.

Quarter-by-quarter ownership
FLAGSHIP HARBOR ADVISORS, LLC ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$273,338
-16.2%
6,022
+3.6%
0.02%
-14.8%
Q2 2023$326,341
+37.0%
5,813
+10.4%
0.03%
+22.7%
Q1 2023$238,185
+15.7%
5,266
+3.9%
0.02%
+4.8%
Q4 2022$205,933
-37.2%
5,066
+1.0%
0.02%
-44.7%
Q3 2022$328,000
+6.8%
5,016
-0.7%
0.04%
+11.8%
Q2 2022$307,000
-4.7%
5,052
-1.4%
0.03%
+9.7%
Q1 2022$322,000
-13.2%
5,124
+4.8%
0.03%
-11.4%
Q4 2021$371,000
-50.3%
4,891
+6.1%
0.04%
-56.2%
Q3 2021$746,0000.0%4,6080.0%0.08%0.0%
Q2 2021$746,000
+96.8%
4,608
+48.1%
0.08%
+86.0%
Q1 2021$379,000
-19.2%
3,111
+1.5%
0.04%
-25.9%
Q4 2020$469,000
+86.9%
3,065
+1.8%
0.06%
+70.6%
Q3 2020$251,000
-7.4%
3,010
-18.6%
0.03%
-15.0%
Q2 2020$271,000
+79.5%
3,700
+4.2%
0.04%
+33.3%
Q1 2020$151,000
-6.8%
3,550
+33.1%
0.03%
+7.1%
Q4 2019$162,000
+45.9%
2,667
-1.6%
0.03%
+27.3%
Q3 2019$111,000
-28.4%
2,709
-18.1%
0.02%
-31.2%
Q2 2019$155,000
+31.4%
3,3090.0%0.03%
+33.3%
Q1 2019$118,000
+53.2%
3,309
+22.1%
0.02%
+26.3%
Q4 2018$77,000
+600.0%
2,709
+918.4%
0.02%
+850.0%
Q3 2018$11,000
-47.6%
266
-27.3%
0.00%
-50.0%
Q2 2018$21,0003660.00%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q3 2022
NameSharesValueWeighting ↓
Versant Venture Management, LLC 498,558$32,581,00055.55%
NEA Management Company, LLC 1,590,002$103,907,0005.19%
ARK Investment Management 8,237,122$538,296,0003.75%
Nikko Asset Management Americas, Inc. 4,262,736$277,078,0003.54%
CLOUGH CAPITAL PARTNERS L P 414,767$27,105,0002.89%
Integral Health Asset Management, LLC 220,000$14,377,0002.79%
PLUSTICK MANAGEMENT LLC 50,000$3,268,0002.48%
HC Advisors, LLC 53,944$3,525,0002.43%
Green Alpha Advisors, LLC 27,466$1,795,0001.52%
EFG Asset Management (North America) Corp. 84,356$5,516,0001.28%
View complete list of CRISPR THERAPEUTICS AG shareholders